Journal ArticleDOI
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Stefan S. Bielack,Beate Kempf-Bielack,Günter Delling,G. Ulrich Exner,Silke Flege,Knut Helmke,Rainer Kotz,Mechthild Salzer-Kuntschik,M. Werner,Winfried Winkelmann,Andreas Zoubek,Heribert Jürgens,Kurt Winkler +12 more
Reads0
Chats0
TLDR
Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis.Abstract:
PURPOSE: To define prognostic factors for response and long-term outcome for a wide spectrum of osteosarcomas, extending well beyond those of the typical young patient with seemingly localized extremity disease. PATIENTS AND METHODS: A total of 1,702 consecutive newly diagnosed patients with high-grade osteosarcoma of the trunk or limbs registered into the neoadjuvant studies of the Cooperative Osteosarcoma Study Group before July 1998 were entered into an analysis of demographic, tumor-related, and treatment-related variables, response, and survival. The intended therapeutic strategy included preoperative and postoperative chemotherapy with multiple agents as well as surgery of all operable lesions. RESULTS: Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis. Actuarial 10-year overall and event-free survival rates were 59.8% and 48.9%. Among the variables assessable at diagnosis, patient age (actuarial 10-y...read more
Citations
More filters
Journal ArticleDOI
Imaging of Primary Malignant Bone Tumors (Nonhematological)
TL;DR: Primary malignant bone tumors are uncommon and are diagnosed typically based on radiographic and microscopic findings combined with clinical and demographic features.
Journal ArticleDOI
Prediction of response to neoadjuvant chemotherapy in osteosarcoma using dual-phase 18 F-FDG PET/CT
Byung Hyun Byun,Sung Hoon Kim,Sang Moo Lim,Ilhan Lim,Chang-Bae Kong,Won Seok Song,Wan Hyeong Cho,Dae-Geun Jeon,Soo-Yong Lee,Jae-Soo Koh,Soo Kyo Chung +10 more
TL;DR: The histological response after NAC could be predicted by using RImean1 before the initiation of NAC in osteosarcoma, and the combined use of SUV and RI values may provide a better prediction.
Journal ArticleDOI
Intraarterial Chemotherapy for Extremity Osteosarcoma and MFH in Adults
TL;DR: A neoadjuvant chemotherapy protocol using combined intraarterial and intravenous agents to treat high-grade osteosarcoma and malignant fibrous histiocytoma of bone in an attempt to improve survival compared favorably with those reported in the current literature.
Journal ArticleDOI
Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway
TL;DR: The findings indicate that high expression of GAL1 is associated with distant metastasis of OS patients, and knockdown of G AL1 inhibits growth and invasion of OS cells possibly through inhibition of the MAPK/ERK pathway, suggesting that GAL 1 may represent a potential target for the treatment of cancer.
Journal ArticleDOI
Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma.
Jianda Xu,Sujia Wu,Xin Shi +2 more
TL;DR: Reversion‐inducing cysteine‐rich protein with Kazal motifs (RECK), a novel membrane‐anchored matrix metalloproteinase inhibitor, has been shown to be associated with prognosis and suppress tumor progression through angiogenesis inhibition in many cancers.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Book ChapterDOI
Regression Models and Life-Tables
TL;DR: The analysis of censored failure times is considered in this paper, where the hazard function is taken to be a function of the explanatory variables and unknown regression coefficients multiplied by an arbitrary and unknown function of time.
Journal Article
Evaluation of survival data and two new rank order statistics arising in its consideration.
Journal ArticleDOI
Underrepresentation of patients 65 years of age or older in cancer-treatment trials.
TL;DR: There is substantial under representation of patients 65 years of age or older in studies of treatment for cancer, and the reasons should be clarified, and policies adopted to correct this underrepresentation.